Journal Article

DKFZ-2025-01148

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Availability and use of PET in patients with brain tumours - a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) survey.

Mair, M. J. ; Lohmann, P. ; Galldiks, N. ; Belting, M. ; Brandal, P. ; Broen, M. P. G. ; Cicone, F. ; Daisne, J.-F. ; Ducray, F. ; Ehret, F.DKFZ* ; Furtner, J. ; Jakola, A. S. ; Niyazi, M. ; Pellerino, A. ; Rasschaert, M. ; Razis, E. ; Sahm, F.DKFZ* ; Smits, M. ; Tolboom, N. ; Verger, A. ; Le Rhun, E. ; Minniti, G. ; Weller, M. ; Preusser, M. ; Albert, N. L.

2025
Springer-Verl. Heidelberg [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1007/s00259-025-07366-0

Abstract: Positron emission tomography (PET) is increasingly used in neuro-oncology. However, little is known about its application across European institutions and reasons for variable implementation.Between June and August 2024, members of the European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) completed a cross-sectional online survey on PET use in neuro-oncological practice.Overall, 103 replies from 20 countries were received. A PET facility was available at 96/103 (93.2%) sites, of whom 74 (77.1%) performed PET in patients with brain tumours. Reasons for not performing PET included limited availability of tracers (14/29, 48.3%), high cost (11/29, 37.9%), and PET perceived unnecessary (8/29, 27.6%). Of sites performing PET, 69/74 (93.2%) reported use in glioma, 58/74 (78.4%) in brain metastasis, 52/74 (70.3%) in meningioma, and 46/74 (62.2%) in CNS lymphoma. Amino acid PET was performed at 62/71 centres (87.3%; 3 not reported [n.r.]), most frequently in glioma (58/59, 98.3%, 3 n.r.) and for differentiation of treatment-related changes from tumour progression (58/59, 98.3%). Somatostatin receptor (SSTR) PET was performed at 50/68 sites (73.5%, 6 n.r.), mainly in meningioma (48/49, 98.0%), for patient selection before radioligand therapy (41/49, 83.7%) and for radiotherapy target volume definition (33/49, 67.3%). Unrestricted coverage by statutory health insurance was reported by 46/59 (78.0%) centres for amino acid PET and 33/49 (67.3%) for SSTR PET.PET use in neuro-oncology is variable across EORTC-BTG sites. Generation of evidence in clinical trials and surveys including non-academic institutions are needed to guide implementation in clinical practice.

Keyword(s): Brain metastasis ; Glioma ; Imaging ; Meningioma ; Positron emission tomography

Note: Volume 52, pages 4627–4638

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Berlin (BE01)
2. KKE Neuropathologie (B300)
3. DKTK HD zentral (HD01)

Research Program(s):

1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2025

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Springer ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---